Solithromycin, also known as CEM-101 and OP-1068, is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections. It is expected to be the first macrolide antibiotic available in intravenous, oral, and pediatric suspension formulations in over 20 years. Solithromycin exhibits excellent in vitro activity against a broad spectrum of Gram-positive respiratory tract pathogens, including macrolide-resistant strains. Solithromycin has activity against a wide variety of pathogens, and further research is being conducted for other infections.
Bacterial inhibitor Related Products:
Pretomanid; Pyrazinamide; Sulfanilamide; Walrycin B; Daptomycin; Tigecycline; Rifabutin; Biapenem; Teicoplanin; Cefditoren Pivoxil; Cefdinir; Azithromycin; Trimethoprim; Vancomycin HCl; Amoxicillin; Dalbavancin; Cefoxitin acid; Ceftibuten dihydrate; Besifloxacin; Cefditoren; Dalbavancin HCl; Cefoxitin Sodium; Besifloxacin Hydrochloride; Pleuromutilin